Key TakeawaysChina’s innovation engine is reinforced by pro-biotech policy, four regional clusters, rapid trial execution, and patient availability, with projections suggesting substantial future FDA approvals from China-origin assets.Capital deployment is polarizing into mega-rounds, while broader competition intensifies amid NIH funding contraction; nonetheless, most leaders anticipate higher R&D spend and increased fundraising activity.Modality priorities have rotated […]
